CpG motifs behave as immunologic adjuvant in the peptide-based vaccine therapy of cancer  

出　　处：《中华肿瘤杂志》2007年第11期M0004-M0004,共1页Chinese Journal of Oncology

摘　　要：Synthetic peptides representing epitopes for antigen-specific CTL have been considered as prime candidates for vaccine development. However, in vivo administration of the peptides can activate T-cell response in some cases but can induce T-cell tolerance in others. The outcome of the CTL response to a peptide challenge is dictatedSynthetic peptides representing epitopes for antigen-specific CTL have been considered as prime candidates for vaccine development. However, in vivo administration of the peptides can activate T-ceU response in some cases but can induce T-cell tolerance in others. The outcome of the CTL response to a peptide challenge is dictated in great part by the activation status of antigen-presenting cell （APC）. In the activation of APC, such as dendritic cells （DC）, the Toll-like receptor （TLR） plays an important role. Ligation of TLRs by relevant ligands leads to significant enhancement of the antigen-presenting capacity of DC to naive CTL. The mechanism consists of increase in a） expression of peptide/MHC complexes, b） expression of co-stimulatory molecules （ CD80/86 ） and c ） cytokine secretion （ IL-12, IFN-α）. E. Celis in a recent paper （ Cancer Res, 2007, 67 ： 7945-7947 ） reviewed the research of his group on the use of synthetic oligodeoxynucleotides containing CpG motifs which activate DC by ligation to TLR-9 in the treatment of cancer.

关 键 词：CPG基序 免疫佐剂 癌症 基因治疗 肽 疫苗 

分 类 号：R392[医药卫生—免疫学]